WN:TSXGeorge Weston Limited Analysis
Data as of 2026-06-30 - not real-time
CA$102.55
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
George Weston Limited is currently trading just below its 52‑week high, with the market price hovering near the 20‑day SMA and comfortably above the 50‑day SMA, indicating short‑term strength. The RSI sits in the mid‑50s, suggesting neither overbought nor oversold conditions, while the MACD shows a bearish histogram that is narrowing, hinting at a possible swing to the upside. A negative beta means the stock tends to move opposite to the broader market, providing a defensive cushion during equity sell‑offs. Volatility over the past month is elevated at roughly 21%, reflecting higher price swings but also offering entry opportunities. Fundamental metrics reveal a solid operating margin of about 8% and free cash flow generation exceeding $4.8 billion, supporting the current dividend payout. The dividend payout ratio is under 45%, and the company’s cash flow comfortably covers the 1.26% yield, indicating sustainability. A discounted cash‑flow model values the shares around $158, well above the current price, implying a material undervaluation.
Analyst consensus remains bullish with a “buy” recommendation, and the target price median of $114 reinforces upside potential. Recent news shows the stock repeatedly edging closer to its 52‑week high, out‑performing the market on several trading days, which adds momentum to the technical picture. The grocery and drug‑store segments benefit from stable consumer demand, while the real‑estate arm provides diversified cash‑flow resilience. Debt levels are high relative to equity, but the strong operating cash flow and low payout ratio mitigate default concerns. Regulatory risk is moderate given exposure to food safety and pharmacy regulations, yet the company’s long history and brand strength buffer potential shocks. Geographic concentration in Canada limits exposure to foreign economic turbulence, keeping currency risk low. Overall, the combination of defensive fundamentals, attractive valuation gap, and supportive price action justifies a positive stance across horizons.
Analyst consensus remains bullish with a “buy” recommendation, and the target price median of $114 reinforces upside potential. Recent news shows the stock repeatedly edging closer to its 52‑week high, out‑performing the market on several trading days, which adds momentum to the technical picture. The grocery and drug‑store segments benefit from stable consumer demand, while the real‑estate arm provides diversified cash‑flow resilience. Debt levels are high relative to equity, but the strong operating cash flow and low payout ratio mitigate default concerns. Regulatory risk is moderate given exposure to food safety and pharmacy regulations, yet the company’s long history and brand strength buffer potential shocks. Geographic concentration in Canada limits exposure to foreign economic turbulence, keeping currency risk low. Overall, the combination of defensive fundamentals, attractive valuation gap, and supportive price action justifies a positive stance across horizons.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price above 20‑day and 50‑day SMAs
- RSI in neutral zone with narrowing MACD histogram
- Recent price rallies toward 52‑week high
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value indicates sizable upside
- Stable free cash flow supporting dividend
- Defensive sector positioning with modest growth
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Long‑term undervaluation relative to intrinsic value
- Diversified revenue from grocery, pharmacy, and real estate
- Resilient consumer demand and low currency exposure
Key Metrics & Analysis
Financial Health
Revenue Growth4.20%
Profit Margin1.79%
P/E Ratio38.0
ROE19.38%
ROA6.95%
Debt/Equity163.63
P/B Ratio9.5
Op. Cash FlowCA$6.8B
Free Cash FlowCA$4.9B
Technical Analysis
TrendBullish
RSI53.5
SupportCA$96.06
ResistanceCA$106.17
MA 20CA$102.65
MA 50CA$98.90
MA 200CA$95.09
MACDBearish
VolumeIncreasing
Fear & Greed Index89.91
Valuation
Fair ValueCA$157.93
Target PriceCA$106.57
Upside/Downside3.92%
GradeUndervalued
TypeBlend
Dividend Yield1.26%
Risk Assessment
Beta-0.39
Volatility21.16%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.